ZURICH/BERLIN, May 27 (Reuters) - The Swiss blue-chip SMI was seen opening 0.4 percent higher at 9,701 points on Monday, according to premarket indications by bank Julius Baer .
Here are some of the main factors that may affect Swiss stocks:
The drugmaker on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.
Separately, Novartis’ breast cancer treatment alpslisib, to be marketed under the brand name Piqray, also won FDA approval on Friday.
The Swatch Group - 8.00 CHF/shr dividend
* Medartis said it has named a new CEO, Cristoph Broennimann
* DKSH Holding said it bought a specialty chemicals distributor in Benelux
* Santhera said it has submitted a marketing authorization application for Puldysa for respiratory dysfunction in patients with Duchenne muscular dystrophy to the European Medicines Agency.
* Aevis Victoria said it placed 61% of Infracore’s share capital
Non-farm payrolls for the first quarter due at 0630 GMT. (Reporting by Zurich newsroom and Berlin Speed Desk)